Zhitong Financial APP learned that according to the disclosure of the HKEx on April 29th, Shanghai Yingwei Medical Devices Co., Ltd. submitted the form to the main board of the HKEx, with Goldman Sachs Group and China International Capital Corporation as co-sponsors.
Invid is China's leading provider of integrated solutions for non-vascular interventional surgery with a global vision. According to CIC, since its establishment in 2009, the company has established a leading proprietary technology platform and formed economies of scale. It has become one of the few companies in the world that can provide endoscopes, active medical devices and passive consumables integration solutions for all major medical specialties for non-vascular interventional surgery in urology, gastroenterology, hepatobiliary surgery, respiratory, thoracic surgery, otorhinolaryngology, gynecology and general surgery.
The company has established a strong brand reputation and market-tested commercial network in China and around the world. Since the first product was approved in China in 2010, it has accumulated more than 10 years of sales and marketing experience to establish a commercial network and sell products in more than 60 countries on five continents. In China, the company's products have penetrated into more than 1500 hospitals, including more than 400 tertiary hospitals and more than 1100 secondary hospitals. As the company commercializes more products and expands its sales network, the company's revenue has increased from 137.3 million yuan in 2020 to about 255 million yuan in 2021. In China, the company's revenue increased by 103.5% from 89.1 million yuan in 2020 to about 181 million yuan in 2021. The company's revenue from endoscope sales was 51.4 million yuan in 2020, an increase of 113.6 percent to about 110 million yuan in 2021.
In 2020 and 2021, the company's revenue was approximately RMB 137 million and RMB 255 million respectively, while the gross profit was approximately RMB 86.832 million and RMB 162 million over the same period.